DIAGNOSIS, PROGNOSTICATION AND TREATMENT OF MYELODYSPLASTIC SYNDROMES (MDS) IN DAILY PRACTICE: RESULTS FROM THE DUTCH POPULATION-BASED PHAROS MDS REGISTRY

被引：0
作者：
Dinmohamed, A. [1 ]
Visser, O. [2 ]
Posthuma, W. [3 ]
Huijgens, P. [2 ,4 ]
Sonneveld, P. [1 ]
van de Loosdrecht, A. [4 ]
Jongen-Lavrencic, M. [1 ]
机构：
[1] Erasmus MC Canc Inst, Hematol, Rotterdam, Netherlands
[2] Comprehens Canc Ctr Netherlands, Registrat & Res, Utrecht, Netherlands
[3] Reinier de Graaf Grp, Internal Med, Delft, Netherlands
[4] Vrije Univ Amsterdam, Med Ctr, Hematol, Amsterdam, Netherlands
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1216
引用
收藏
页码：487 / 487
页数：1
相关论文
共 50 条
  • [41] TRANSFUSIONS AND PRESENCE OF RINGSIDEROBLASTS INFLUENCE HEPCIDIN AND NTBI LEVELS IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS) - A REPORT FROM THE EUROPEAN LEUKEMIANET MDS REGISTRY
    de Swart, L.
    Reiniers, C.
    Bagguley, T.
    Van Marrewijk, C.
    Bowen, D.
    Cermak, J.
    Hellstrom-Lindberg, E.
    Tatic, A.
    Symeonidis, A.
    Huls, G.
    Panagiotidis, P.
    Garelius, H.
    Culligan, D.
    Krejci, M.
    Droste, J.
    Smith, A.
    Swinkels, D.
    de Witte, T.
    LEUKEMIA RESEARCH, 2015, 39 : S106 - S107
  • [42] Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry
    Hoeks, Marlijn
    Yu, Ge
    Langemeijer, Saskia
    Crouch, Simon
    de Swart, Louise
    Fenaux, Pierre
    Symeonidis, Argiris
    Cermak, Jaroslav
    Hellstrom-Lindberg, Eva
    Sanz, Guillermo
    Stauder, Reinhard
    Holm, Mette Skov
    Mittelman, Moshe
    Madry, Krzysztof
    Malcovati, Luca
    Tatic, Aurelia
    Almeida, Antonio Medina
    Germing, Ulrich
    Savic, Aleksandar
    Simec, Njetocka Gredelj
    Culligan, Dominic
    Itzykson, Raphael
    Guerci-Bresler, Agnes
    Slama, Borhane
    van de Loosdrecht, Arjan
    van Marrewijk, Corine
    Droste, Jackie
    Blijlevens, Nicole
    van Kraaij, Marian
    Bowen, David
    de Witte, Theo
    Smith, Alex
    HAEMATOLOGICA, 2020, 105 (03) : 640 - 651
  • [43] Quality of life (QoL) in myelodysplastic syndromes (MDS): an update of results from US & European patient forums
    Heptinstall, K.
    LEUKEMIA RESEARCH, 2007, 31 : S107 - S107
  • [44] Response to Treatment Among SF3B1 Mutated Myelodysplastic Syndromes (MDS): A Case-Control Study from the MDS Clinical Research Consortium (MDS CRC)
    Komrokji, Rami S.
    DeZern, Amy E.
    Zell, Katrina
    Al Ali, Najla H.
    Padron, Eric
    Estling, Christopher
    Zimmerman, Cassie
    Hand, Wesley
    Brown, Francis
    Rizzo, Nicole
    Barnard, John
    Roboz, Gail J.
    Carraway, Hetty E.
    Maciejewski, Jaroslaw P.
    List, Alan F.
    Garcia-Manero, Guillermo
    Steensma, David P.
    Sekeres, Mikkael A.
    BLOOD, 2015, 126 (23)
  • [45] Labile Plasma Iron (LPI) Is a Clinical Indicator of Overt Iron Overload in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) from the European Leukemianet MDS Registry
    De Swart, Louise
    Reiniers, Chloe
    Bagguley, Tim
    Bowen, David
    Cermak, Jaroslav
    Hellstrom-Lindberg, Eva
    Tatic, Aurelia
    Symeonidis, Argiris
    Huls, Gerwin
    Panagiotidis, Panagiotis
    Garelius, Hege
    Culligan, Dominic
    Krejci, Marta
    van Marrewijk, Corine
    Droste, Jackie
    Smith, Alexandra
    Swinkels, Dorine W.
    de Witte, Theo
    BLOOD, 2015, 126 (23)
  • [46] TREATMENT WITH VNP40101M (CLORETAZINE?) IN PATIENTS WITH HIGH RISK MYELODYSPLASTIC SYNDROMES (MDS): RESULTS OF A SUBSET POPULATION IN A PHASE II STUDY
    Mufti, G.
    Rizzieri, D.
    Vey, N.
    Hudak, D.
    Karp, J.
    Giles, E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 94 - 95
  • [47] Dysplasia Has A Differential Diagnosis: Distinguishing Genuine Myelodysplastic Syndromes (MDS) From Mimics, Imitators, Copycats and Impostors
    David P. Steensma
    Current Hematologic Malignancy Reports, 2012, 7 : 310 - 320
  • [48] TREATMENT OF HIGHER-RISK MYELODYSPLASTIC SYNDROME (MDS) WITH AZACITIDINE: A 4-YEAR POPULATION-BASED ANALYSIS FROM BRITISH COLUMBIA, CANADA
    Ankenman, M.
    Hogge, D.
    Narayanan, S.
    Power, M.
    Abou Mourad, Y.
    Barnett, M.
    Nantel, S.
    Sutherland, H.
    Forrest, D.
    Broady, R.
    Toze, C.
    Gerrie, A.
    Song, K.
    Nevill, T.
    HAEMATOLOGICA, 2015, 100 : 240 - 241
  • [49] Dysplasia Has A Differential Diagnosis: Distinguishing Genuine Myelodysplastic Syndromes (MDS) From Mimics, Imitators, Copycats and Impostors
    Steensma, David P.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2012, 7 (04) : 310 - 320
  • [50] Allogeneic stem cell transplant for myelodysplastic syndromes: results of 291 patients from Spanish MDS Registry. Subanalysis on low-risk patients
    Diez-Campelo, M.
    Cordoba, I.
    Gomez-Garcia, V.
    Martino, R.
    Sanz, G.
    Insunza, A.
    Bernal, T.
    Duarte, R.
    Amigo, M. L.
    Xicoy, B.
    Tormo, M.
    Iniesta, F.
    Bailen, A.
    Benlloch, L.
    Lopez-Villar, O.
    del Canizo, M. C.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S435 - S435
12345